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Abstract
A central question is how the conformational changes of proteins affect their function and the inhibition of this function by drug
molecules. Many enzymes change from an open to a closed conformation upon binding of substrate or inhibitor molecules. These
conformational changes have been suggested to follow an induced-fit mechanism in which the molecules first bind in the open
conformation in those cases where binding in the closed conformation appears to be sterically obstructed such as for the HIV-1
protease. In this article, we present a general model for the catalysis and inhibition of enzymes with induced-fit binding mechanism.
We derive general expressions that specify how the overall catalytic rate of the enzymes depends on the rates for binding, for the
conformational changes, and for the chemical reaction. Based on these expressions, we analyze the effect of mutations that mainly
shift the conformational equilibrium on catalysis and inhibition. If the overall catalytic rate is limited by product unbinding, we find
that mutations that destabilize the closed conformation relative to the open conformation increase the catalytic rate in the presence
of inhibitors by a factor exp(∆∆GC/RT ) where ∆∆GC is the mutation-induced shift of the free-energy difference between the
conformations. This increase in the catalytic rate due to changes in the conformational equilibrium is independent of the inhibitor
molecule and, thus, may help to understand how non-active-site mutations can contribute to the multi-drug-resistance that has been
observed for the HIV-1 protease. A comparison to experimental data for the non-active-site mutation L90M of the HIV-1 protease
indicates that the mutation slightly destabilizes the closed conformation of the enzyme.
Keywords: enzyme dynamics, induced fit, conformational selection, HIV-1 protease, non-active-site mutation, multi-drug
resistance
1. Introduction
The function of proteins often involves conformational changes
during the binding or unbinding of ligand molecules [1, 2].
Central questions are how these conformational changes are
coupled to the binding processes, and how they affect the func-
tion of the proteins and the inhibition of this function by drug
molecules. For some proteins, a conformational change has
been proposed to occur predominantly after a binding or un-
binding process [3–6], apparently ‘induced’ by this process [7].
For other proteins, a conformational change has been suggested
to occur predominantly prior to a binding or unbinding process
[8–16], which has been termed ‘conformational selection’ since
the ligand appears to select a conformation for binding or un-
binding [17–19]. Binding via conformational selection implies
induced-change unbinding, and vice versa, since the ordering of
events is reversed in the binding and unbinding direction [16].
In this article, we extend classical models of enzyme catal-
ysis and inhibition [20] by including a conformational change
during the binding and unbinding of substrate, product, or in-
hibitor molecules. Our aim is to investigate how the confor-
mational change affects the catalytic rates in the presence and
absence of inhibitor molecules, and how non-active-site muta-
tions that shift the conformational equilibrium alter these cat-
alytic rates. We focus on enzymes with induced-change bind-
ing mechanism since many enzymes close rather tightly over
substrate or inhibitor molecules during binding. Binding via
an induced-change mechanism, i.e. prior to the change from
the ‘open’ to the ‘closed’ conformation of these enzymes, is
required if the entry and exit of the ligand molecules are steri-
cally obstructed in the closed conformation [3]. In the reverse
direction, the ligands then unbind via conformational selection
because the change from the closed to open conformation has
to occur prior to the unbinding process. Classical models of
competitive inhibition, in which the inhibitor binds to the same
site as the substrate, involve four states: an empty state E of
the enzyme, and three states ES, EP , and EI in which the en-
zyme is bound to a substrate molecule S, a product molecule
P, or an inhibitor molecule I [20]. In our extended model for
enzymes with induced-change binding mechanism, the enzyme
can adopt two conformations, an ‘open’ conformation 1, and
a ‘closed’ conformation 2. The model has seven states be-
cause induced-change binding involves an open state E1S and
a closed state E2S with bound substrate, two such states E1P
and E2P with bound product, and two states E1I and E2I with
bound inhibitor, besides the empty state (see fig. 1).
With our extended model, we derive general expressions
for the catalytic rates of enzymes with induced-change binding
mechanism. The catalytic rates of these enzymes depend on (i)
the binding and unbinding rates of substrate, product, and in-
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Figure 1: 7-state model for catalysis and inhibition of an enzyme with induced-fit binding mechanism. In this model, substrate
molecules S and inhibitor molecules I first bind in conformation E1 of the enzyme. These binding events induce changes into
conformation E2 in which the substrate S is converted into the product P . In the case of the HIV-1 protease, the conformation E1
corresponds to the semi-open conformation, and the conformation E2 to the closed conformation.
hibitor molecules in the open conformation 1, (ii) the forward
and backward rates of the catalytic step, and (iii) the transi-
tion rates between the two conformations in the bound states of
the enzyme (see eqs. (2) to (8)). Our general expressions for
the catalytic rates lead to an effective four-state model with a
single substrate-bound state, a single product-bound, and a sin-
gle inhibitor-bound state (see fig. 2), but with effective on- and
off-rates of substrate and product molecules that depend on the
conformational transition rates (see eqs. (6) to (8)).
The role of the conformational changes for catalysis and in-
hibition can be revealed by non-active-site mutations that slightly
shift the conformational equilibrium, but do not interfere di-
rectly with binding and catalysis in the active site of the en-
zymes. Several groups have suggested that such shifts in the
conformational equilibrium might explain why non-active-site
mutations can contribute to multi-drug resistance [36, 42, 43],
i.e. to an increase of catalytic rates in the presence of different
inhibitory drugs. Based on our general results for enzymes with
induced-change binding mechanism, we investigate how these
mutations affect catalysis and inhibition, and distinguish two
cases. In case 1, the maximum catalytic rate of the enzyme is
limited by the unbinding of the product. We find that the cat-
alytic rate in the presence of inhibitors depends exponentially
on the mutation-induced change ∆∆GC of the free-energy dif-
ference between the two conformations of the enzyme in this
case (see eqs. (25) and (27)). Non-active-site mutations with
∆∆GC > 0 that slightly destabilize the closed conformation
2 relative to the open conformation 1 of the enzyme lead to
an increase in the catalytic rate, irrespective of the inhibitor.
Such non-active-site mutations thus contribute to a multi-drug-
resistance of the enzyme. In case 2, the maximum catalytic rate
of the enzyme is limited by the forward rate of the catalytic
step. In this case, mutation-induced changes of the conforma-
tional equilibrium have no effect on the catalytic rate in the
presence of inhibitors. A comparison with experimental data
for the non-active-site mutation L90M of the HIV-1 protease
indicates that this enzyme appears to follow case 1, which im-
plies that non-active-site mutations that slightly destabilize the
closed conformation contribute to multi-drug resistance.
2. Catalysis and inhibition of an enzyme with induced-fit
binding mechanism
We consider an enzyme with two conformations E1 and
E2 that binds its substrate S via an induced-change mechanism
E1 
 E1S 
 E2S. We assume that the catalytic step occurs
in conformation 2 of the enzyme, and that the inhibitor I binds
to the same site as the substrate (‘competitive inhibition’). The
catalytic cycle of the enzyme and the inhibition of this cycle
then can be described by the 7-state model shown in fig. 1.
The catalytic rate depends on the 14 forward and backward
rates between the 7 states of the model. These rates are:
(i) The binding rates s+[S], p+[P ], and i+[I] and unbinding
rates s−, p−, and i− of substrate, product and inhibitor molecules
in conformation 1 of the enzyme. Here, [S], [P ], and [I] denote
the concentrations of these molecules.
(ii) The forward and reverse rates of the catalytic step kf and
kr.
(iii) The conformational transition rates s12, s21, p12, p21, i12
and i21 between the substrate-bound statesE1S andE2S, product-
bound states E1P and E2P , and inhibitor-bound states E1I
and E2I . We assume that the bound states E2S, E2P , and
E2I with conformation 2 of the enzyme are the ground-state
conformations, while the conformations E1S, E1P , and E1I
with conformation 1 of the enzyme are excited-state conforma-
tions. This assumption is valid if experimental structures indi-
cate that an enzyme adopts conformation 1 in its unbound state
and conformation 2 in its bound states, since the experimental
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Figure 2: Effective 4-state model for catalysis and inhibition of
an enzyme with induced-fit binding mechanism. The effective
binding and unbinding rates of substrate and product given in
eqs. (6) to (8) connect this model to the 7-state model of fig. 1.
structures correspond to ground-state conformations. The as-
sumption implies
s21  s12 , p21  p12, and i21  i12 (1)
i.e. the excitation rates s21, p21, and i21 are much smaller than
the corresponding ground-state relaxation rates s12, p12, and
i12.
One of our main results is that the catalytic rate can be writ-
ten in the Michaelis-Menten form (see Appendix A)
k ' kmax[S]
(1 + [I]/Ki)Km + [S]
(2)
with
kmax ' kfpof
kf + kr + pof
(3)
Km ' (kf + sof)pof + krsof
(kf + kr + pof)son
(4)
Ki =
i21i−
i12i+
(5)
and
son =
s12s+
s12 + s−
(6)
sof =
s21s−
s12 + s−
(7)
pof =
p21p−
p12 + p−
(8)
for negligible product concentration [P ] or negligible product
binding rate p+[P ]. In deriving eqs. (2) to (8) from the ex-
act solution, we have assumed that the excitation rate p21 in the
product-bound state is much smaller than the relaxation rate s12
in the substrate-bound state, besides eq. (1) (see Appendix A).
This assumption is reasonable if the relaxation rates s12 and p12
in the substrate- and product-bound states are of similar magni-
tude, since p21  p12 (see eq. (1)) then implies also p21  s12.
Our general results for the 7-state model of fig. 1 lead to
an effective 4-state model of catalysis and inhibition, see fig. 2.
The catalytic rate of this 4-state model is described by eqs. (2) to
(4) with Ki = iof/ion for negligible product concentration [P ].
The effective 4-state model has the same structure as classical
4-state models for competitive inhibition [20], but includes two
conformations for the enzyme. The rates son and sof in eqs. (6)
and (7) can be understood as the effective on- and off-rates of
the substrate, i.e. as the effective forward and backward rates
between the unbound state E1 and the bound ground state E2S.
Similarly, pof in eq. (8) can be understood as the effective un-
binding rate of the product from the bound ground state E2P .
The expressions in eqs. (6) and (8) for the effective on- and
off-rates result here from an analysis of steady-state catalytic
rates, but are identical with previously derived expressions for
the effective relaxation rates of two-step binding processes that
involve a conformational change [16, 56] (see appendix B).
3. Effect of non-active site mutations on catalysis
In general, mutations can affect all rate constants of the 7-
state model shown in fig. 1, in particular if they are located
in the binding site, or active site, of the enzyme. Non-active-
site mutations, in contrast, may mainly affect the conforma-
tional equilibrium of the bound ground states and excited states.
The conformational equilibrium constant s21/s12 of the two
substrate-bound states E1S and E2S and the equilibrium con-
stant p21/p12 of the product-bound states E1P and E2P de-
pend on the free-energy energy differences between the states.
These differences can be decomposed into the free-energy dif-
ference ∆GC = G(E2) − G(E1) between the conformations
and the differences in the binding free energy of substrate and
product molecules in the two conformations of the enzyme. If
a non-active-site mutation only affects the conformational free-
energy difference but not the binding free-energy differences
between the conformations, we have
s′21/s
′
12
s21/s12
= exp(∆∆GC/RT ) (9)
p′21/p
′
12
p21/p12
= exp(∆∆GC/RT ) (10)
where the prime indicates rates of the mutant. Here, ∆∆GC =
∆G′C−∆GC is the mutation-induced change of the free-energy
difference between the conformations.
If the relaxation rates s12 and p12 into the bound ground
states are much larger than the corresponding unbinding rates
s− and p− from the excited states, we obtain
s′on
son
' 1 (11)
s′of
sof
' exp(∆∆GC/RT ) (12)
p′of
pof
' exp(∆∆GC/RT ) (13)
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from eqs. (6) to (8), which simplify to son ' s+, sof ' s21s−/s12,
and pof ' p21p−/p12 in this case. We have assumed here that
the non-active-site mutation does not affect the binding and
unbinding rate constants s+, s−, and p−. Alternatively, the
eqs. (11) and (13) follow from the eqs. (6) to (8) if we assume
that the mutation-induced change of the conformational free-
energy difference mainly affects the excitation rates, which im-
plies s′21/s21 ' exp(∆∆GC/RT ) and s′12 ' s12 for the con-
formational transition rates of the substrate-bound states, and
p′21/p21 ' exp(∆∆GC/RT ) and p′12 ' p12 for the transi-
tion rates of the product-bound states [16]. The non-active-site
mutation thus changes the effective off-rates of substrate and
product molecules by the same factorexp(∆∆GC/RT ), irre-
spective of the binding energies of these molecules, while the
effective on-rates remain the same.
With eqs. (11) to (13), we can now determine the effect of
a non-active-site mutation on the catalytic quantities kmax and
Km of the enzyme, which are given in eqs. (3) and (4). We
assume that the non-active-site mutation does not affect the for-
ward and backward rates kf and kr of the catalytic step, and
consider two cases:
Case 1: kf much larger than pof and sof
If the forward rate kf of the catalytic step is much larger
than the effective off-rates of product and substrate, we obtain
kmax ' kfpof
kf + kr
(14)
Km ' kfpof + krsof
(kf + kr)son
(15)
from eqs. (3) and (4). The effect of the non-active-site mutation
on kmax and Km is then characterized by (see eqs. (11) to (13))
k′max
kmax
' p
′
of
pof
' exp(∆∆GC/RT ) (16)
and
K ′m
Km
' kfp
′
of + krs
′
of
kfpof + krsof
' exp(∆∆GC/RT ) (17)
for k′f ' kf and k′r ' kr. The non-active-site mutation thus
changes kmax and Km by the same factor exp(∆∆GC/RT ).
The ratio kmax/Km of these quantities therefore is not affected
by the mutation:
k′max
K ′m
' kmax
Km
(18)
Case 2: kf and kr much smaller than pof and sof
If the rates kf and kr for the catalytic step are much smaller
than the effective off-rates of substrate and product, we obtain
kmax ' kf (19)
Km ' sof
son
(20)
from eqs. (3) and (4). The effect of the non-active-site mutation
then can be described by
k′max
kmax
' 1 (21)
and
K ′m
Km
' s
′
of
sof
' exp(∆∆GC/RT ) (22)
The non-active-site mutation thus changesKm by the same fac-
tor as in case 1, but does not affect the maximal catalytic rate
kmax. From these equations, we obtain
k′max/K
′
m
kmax/Km
' exp(−∆∆GC/RT ) (23)
4. Effect of non-active-site mutations on inhibition
To quantify the effect of a non-active-site mutation on the
interplay of catalysis and inhibition, we focus now on substrate
and inhibitor concentrations [I] and [S] with [I]  Ki and
[I]Km/Ki  [S]. For such concentrations, a substantial frac-
tion of the enzyme is bound to the inhibitor, and the catalytic
rate of the enzyme is (see eq. (2))
k ' kmaxKi[S]
Km[I]
(24)
and, thus, proportional to the inhibition constant Ki and in-
versely proportional to the inhibitor concentration [I]. For [I]
Ki or [I]Km/Ki  [S], in contrast, the catalytic rate of the en-
zyme is independent of [I] and Ki (see eq. (2)). If the mutant
also fulfills the conditions [I]  K ′i and [I]K ′m/K ′i  [S] at
the considered substrate and inhibitor concentrations, the ratio
of the catalytic rates of mutant and wildtype is
k′
k
' K
′
ik
′
max/K
′
m
Kikmax/Km
(25)
The expression on the right-hand side of this equation has been
termed the ‘vitality’ of the mutant [21]. The vitality depends
on the catalytic quantities kmax and Km and on the inhibition
constant Ki of the wildtype and mutant enzyme.
The inhibition constant Ki, defined in eq. (5), is the dis-
sociation constant of the inhibitor and the enzyme. The con-
stant depends on the free-energy difference G(E2I) − G(E1)
between the bound ground state E2I and the unbound state
E1. This free-energy difference can be composed into the free-
energy difference ∆GC = G(E2) − G(E1) between the con-
formations of the enzyme, and the binding energy ∆GI =
G(E2I) − G(E2) in conformation 2 of the enzyme. The ef-
fect of a mutation on Ki thus can be characterized by
K ′i
Ki
= exp((∆∆GC + ∆∆GI)/RT ) (26)
where K ′i is the inhibition constant of the mutant, and ∆∆GC
and ∆∆GI are the mutation-induced changes of the confor-
mational free-energy difference and the binding free energy in
4
conformation 2. Besides affecting ∆Gc, some non-active-site
mutations that contribute to inhibitor resistance of an enzyme
have been suggested to have an indirect effect on the binding
free energy ∆GI by slightly changing the shape of the bind-
ing pocket in a way that does not interfere with substrate bind-
ing [22–24]. This suggestion concerns inhibitors with a bound
shape that is not confined within the shape or ‘envelope’ of the
bound substrate.
With eq. (26) and the results of the previous section, we
can now determine the vitality of non-active site mutants. We
consider again the two cases of the previous section:
Case 1: kf much larger than pof and sof
If the forward rate of the catalytic step is much larger than
the effective off-rates of product and substrate for both wildtype
and mutant, we obtain the vitality
K ′ik
′
max/K
′
m
Kikmax/Km
' exp((∆∆GC + ∆∆GI)/RT ) (27)
from the eqs. (18) and (26). The effect of the non-active-site
mutation on the free-energy difference between the conforma-
tion thus is reflected by the factor exp(∆∆GC/RT ) in the vi-
tality, while the effect of the mutation on the binding-free en-
ergy of the inhibitor in conformation 2 of the enzyme is re-
flected by the factor exp(∆∆GI/RT ). Eq. (27) indicates that
the change of the conformational free-energy difference induced
by a non-active-site mutation can have a significant effect on the
catalytic rate of the mutant in the presence of the inhibitors.
Case 2: kf and kr much smaller than pof and sof
If the rates for the catalytic step are much smaller than the
effective off-rates of substrate and product, we obtain the vital-
ity
K ′ik
′
max/K
′
m
Kikmax/Km
' exp(∆∆GI/RT ) (28)
from the eqs. (23) and (26). In this case, the vitality is only
affected by the change ∆∆GI in the binding-free energy of the
inhibitor.
5. Comparison with experimental data for the non-active
site mutation L90M of the HIV-1 protease
To illustrate our general results for the effect of non-active-
site mutations on catalysis and inhibition of enzymes with induced-
fit binding kinetics, we consider here the well-studied muta-
tion L90M of the HIV-1 protease as an example. The HIV-1
protease changes from a semi-open to a closed conformation
during binding of substrate or inhibitor molecules. The con-
formational change from the semi-open to the closed confor-
mation has been suggested to occur after the binding process
since binding in the closed conformation appears to be steri-
cally prohibited [25, 26]. The conformational dynamics of the
HIV-1 protease has been studied in NMR experiments [27–29],
by pulsed EPR spectroscopy [30–32], and in molecular dynam-
ics simulations [33–41]. In the native state, the HIV-1 protease
Table 1: Catalytic efficiency of mutant L90M relative to wild-
type HIV-1 protease (data from Maschera et al.[42])
substrate
k′max
kmax
K ′m
Km
k′max/K
′
m
kmax/Km
SQNY-PIVQ 1.3 1.4 0.9
ARVL-AEAM 1.6 1.3 1.3
ATIM-MQRG 1.4 1.6 0.9
PGNF-LQSR – – 0.4
SFNF-PQIT 1.3 1.9 0.8
TLNF-PISP 1.2 1.1 1.1
AETF-YVDG 1.4 1.2 1.2
RKIL-FLDG 1.2 0.9 1.5
fluorogenic 1.4 2 0.7
is a homo-dimer of two identical subunits with 99 residues. The
active site is located in a tunnel at the dimer interface, which
opens and closes via the motion of two ‘flaps’, accompanied
by motion in other regions of the protease. Inhibitors of the
HIV-1 protease that bind to the active site play a central role
in anti-AIDS therapies. However, the efficiency of these ther-
apies is impaired by viral mutations that lead to inhibitor re-
sistance. Mutations that are associated with resistance occur
both in the active site of the HIV-1 protease and distal to the ac-
tive site. While active-site mutations can directly interfere with
catalysis and binding, the contribution of distal, non-active-site
mutations to resistance is not fully clear. Several groups have
suggested that non-active-site mutations of the HIV-1 protease
such as L90M contribute to inhibitor resistance by shifting the
equilibrium between the semi-open and closed conformation of
the protease [36, 42, 43]. Alternative explanations for the mu-
tation L90M include an indirect effect on active-site residues
[44–47], and a reduction of dimer stability [48] since the mu-
tated residue 90 is located at the dimer interface.
Maschera and co-workers [42] have systematically investi-
gated the catalytic efficiency of the wildtype protease and the
mutant L90M with 8 different peptide substrates and a fluo-
rogenic substrate (see Table 1). The mutation L90M leads to a
slight increase of kcat andKm. Averaged over all substrates, the
ratios of the experimental values for the mutant and the wild-
type are k′max/kmax = 1.35±0.05 and K ′m/Km = 1.43±0.14,
while the average value for the ratio of k′max/K
′
m and kmax/Km
is 0.98 ± 0.12. These results are consistent with eqs. (16) to
(18), which indicate a change of kcat and Km by the same
factor exp(∆∆GC/RT ) due to a non-active-site mutation that
mainly affects the conformational equilibrium. From the aver-
age values of k′max/kmax andK
′
m/Km obtained from the data of
Maschera et al., the change in the conformational free-energy
difference ∆∆GC due to the mutation L90M can be estimated
as about 0.2 kcal/mol, which indicates a slight destabilization
of the closed conformation of the HIV-1 protease relative to
the semi-open conformation. However, other groups have re-
ported a decrease of kmax, Km, and kmax/Km due to the mu-
tation L90M for three different substrates [49–51]. In general,
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Table 2: Ratio of dissociation constants K ′D and KD for the
mutant L90M and the wildtype of the HIV-1 protease (calcu-
lated from data of Shuman et al.[54])
inhibitor K ′D/KD
Amprenavir 2.73± 0.67
Indinavir 2.85± 0.71
Nelfinavir 1.99± 0.70
Ritonavir 4.54± 1.68
Saquinavir 2.93± 0.77
the catalytic efficiency of the HIV-1 protease strongly depends
on the experimental conditions, in particular on the pH and salt
concentration [42, 52, 53].
Shuman et al. [54] have measured the dissociation constants
KD and K ′D of the wildtype and the mutant L90M for five dif-
ferent inhibitors with biosensor methods (see Table 2). Within
the experimental errors, the ratios K ′D/KD of the dissociation
constants for the five inhibitors agree with the average value
3.0 ± 0.4 of these ratios. For a non-active-site mutation with
a negligible change ∆∆GI of the binding free energy in the
closed conformation of the protease, we expect a change of KD
by the inhibitor-independent factor exp(∆∆GC/RT ) from eq.
(26) sinceKD is identical with the inhibition constantKi. From
the mean valueK ′D/KD ' 3, we obtain the estimate ∆∆GC '
0.65 kcal/mol for ∆∆GI ' 0, which is somewhat larger than
the estimate ∆∆GC ' 0.2 kcal/mol obtained from the changes
of kmax and Km reported by Maschera et al. (see above).
Inhibition constants Ki and K ′i for the wildtype and mutant
L90M have been measured by several groups for a variety of
inhibitors (see Table 3). The ratios K ′i/Ki differ for different
inhibitors, which appears to indicate mutation-induced changes
∆∆GI in the binding free energy for the closed conforma-
tion that depend on the inhibitor. However, results by different
groups for the same inhibitor also differ (see data in Table 3 for
the inhibitors Indinavir and Saquinavir), possibly due to differ-
ent experimental conditions such as pH or salt concentrations.
Overall, the majority of the experimentally determined ratios
K ′i/Ki for L90M in Table 3 are larger than 1, which may be
interpreted to point towards a destabilization of the closed con-
formation relative to the semi-open, i.e. towards positive values
of ∆∆GC .
6. Conclusions
We have considered here a general 7-state model for the
catalysis and inhibition of enzymes with induced-fit binding
mechanism. This model extends classical models for catalysis
and inhibition [20] by including changes between two different
conformations of the enzymes, and helps to understand how
non-active-site mutations that shift the conformational equilib-
rium can affect catalysis and inhibition. The induced-fit bind-
ing mechanism considered here applies to enzymes such as the
HIV-1 protease that close over ligands in the bound ground-
state conformation in a way that sterically prevents ligand exit
Table 3: Ratio of inhibition constants K ′i and Ki for the mutant
L90M and the wildtype of the HIV-1 protease
inhibitor reference K ′i/Ki
Indinavir [50] 4.1± 0.8
[47] 1.3± 0.3
[49] 0.16± 0.03
Nelfinavir [50] 9.0± 1.5
Ritonavir [50] 3.2± 1.0
Saquinavir [42] 21± 4
[50] 28± 9
[57] 3.0± 1.0
L-735,524 [42] 5.8± 1.7
VX-478 [42] 2.7± 0.3
AG-1343 [42] 3.5± 1.0
ABT-538 [42] 6.7± 2.4
Lopinavir [50] 1.0± 0.6
QF34 [50] 0.9± 0.4
Darunavir (TMC-114) [47] 0.14± 0.04
and entry in this conformation [3, 25, 26]. The unbinding of
product and inhibitor molecules from these enzymes follows
a conformational-selection mechanism since a conformational
change from the closed ground-state conformation to an open
or semi-open exited-state conformation is required prior to lig-
and exit [16]. Our approach can be generalized to enzymes with
other binding mechanisms, e.g. to enzymes with a conformation-
selection binding and induced-fit unbinding mechanism.
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Appendix A. Catalytic rates
We illustrate in this section how eqs. (2) to (8) for the cat-
alytic rate of the 7-state model shown in fig. 1 can be derived
from exact results. To avoid exceedingly long equations, we
focus on the special case with inhibitor concentration [I] = 0.
The derivation in the general case with [I] > 0 is analogous to
the derivation in this special case.
For [I] = 0, the two statesE1I andE2I have zero probabil-
ity. The 7-state model thus reduces to a model with 5 states. The
steady-state probabilities P (E1), P (E1S), P (E2S), P (E2P ),
and P (E1P ) of these 5 states can be calculated from the 5 equa-
tions (see e.g. [55])
P (E1)+P (E1S)+P (E2S)+P (E2P )+P (E1P ) = 1 (A.1)
P (E1S)s− + P (E1P )p− − P (E1)s+[S] = 0 (A.2)
P (E1)s+[S] + P (E2S)s21 − P (E1S)(s12 + s−) = 0 (A.3)
P (E1S)s12 + P (E2P )kr − P (E2S)(s21 + kf ) = 0 (A.4)
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P (E2S)kf + P (E1P )p12 − P (E2P )(kr + p21) = 0 (A.5)
While eq. (A.1) ensures probability normalization, the eqs. (A.2)
to (A.5) are the flux balance conditions for the states E1, E1S,
E2S, and E2P in the steady state, in which the inward flux
into a state equals the outward flux from this state. We have
assumed that the product concentration [P ] or product binding
rate p+[P ] are negligible in eq. (A.2).
The catalytic flux k of the enzyme is defined as the steady-
state flux along the cycle:
k = P (E2S)kf − P (E2P )kr (A.6)
From eqs. (A.1) to (A.6), we obtain the exact result for catalytic
flux
k =
a[S]
b + c[S]
(A.7)
with
a = s+s12kfp21p− (A.8)
b = kfp21p−(s12 + s−) + krs21s−(p12 + p−)
+ s21s−p21p− (A.9)
c = kf (p21p− + (p12 + p21 + p−)s12)s+
+ (kr(p12 + p−) + p21p−)(s12 + s21)s+(A.10)
For p21  p12 and s21  s12 (see eq. (1)), eq. (A.10) can be
simplified to
c ' kf ((p21 + s12)p− + p12s12)s+
+ (kr(p12 + p−) + p21p−)s12s+ (A.11)
If we further assume p21  s12 (see text after eq. (8) for justi-
fication), we obtain
c ' ((kf + kr)(p12 + p−) + p21p−)s12s+ (A.12)
The eqs. (A.8) and (A.12) now lead to the maximal catalytic
flux
kmax =
a
c
' kfp21p−
(kf + kr)(p12 + p−) + p21p−
(A.13)
This expression for the maximal catalytic flux is identical to
eq. (3) with pof given in eq. (8). Similarly, the eqs. (A.9) and
(A.12) lead to an expression for Km = b/c that is identical to
eq. (4) with eqs. (6) to (8).
Appendix B. Effective rates for induced-fit binding
We consider here the induced-fit binding process of an in-
hibitor I to an enzyme that can adopt two conformations E1
and E2:
E1
i+[I]


i−
E1I
i12


i21
E2I (B.1)
In the forward direction of this process, the conformational change
occurs after the binding event, apparently ‘induced’ by this event.
In the reverse direction, the conformational change precedes the
unbinding step. The unbinding of the inhibitor thus follows a
conformational-selection mechanism. Here, i+ and i− are the
rate constants for the binding and unbinding of the inhibitor in
conformation 1 of the enzyme, and i12 and i21 are rates for
the conformational exchange between the bound ground state
E2I and the bound excited state E1I . We assume that the con-
centration [I] of the inhibitor is much larger than the enzyme
concentration, which implies pseudo-first-order kinetics with
approximately constant inhibitor concentration and, thus, con-
stant binding rate i+[I].
The effective on- and off-rates of the two-step process (B.1)
can be determined from the dominant relaxation rate of this pro-
cess [16, 56]. Since the excitation rate i21 of the bound excited
state E1I is much smaller than the relaxation rate i12 into the
bound ground state E2I , the effective off-rate from E2I to E1
is [16, 56]:
iof ' i21i−
i12 + i−
(B.2)
The effective on-rate ion follows from the condition that the ef-
fective equilibrium constant ion/iof of the two-step process has
to be equal to the product (i+/i−)(i12/i21) of the equilibrium
constants for the two substeps. With eq. (B.2), this condition
leads to
ion ' i12i+
i12 + i−
(B.3)
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